Kiniksa Pharmaceuticals International, plc Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc

KNSA

Classement en actions #2969
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prix de l'action
$79.61
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$6.21B
Changement (1 jour)
1.30%
Changement (1 an)
104.18%
Pays
GB
Échange Kiniksa Pharmaceuticals International, plc (KNSA)

Catégorie

Healthcare
Historique des dividendes pour Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (symbole boursier : KNSA) a versé un total de 0 dividendes.
Le total des dividendes (ajusté en fonction des divisions d’actions) est de : 0.00
Rendement du dividende (TTM) : 0
Versements de dividendes pour Kiniksa Pharmaceuticals International, plc (KNSA) de 2026 à 2026
Versements annuels de dividendes
Année Dividende (ajusté pour divisions d’actions) Changez
Pas assez de données pour les dates fournies.
Liste de tous les paiements de dividendes
Année Dividende Changez
Pas assez de données pour les dates fournies.
Dividendes versés par des entreprises similaires ou concurrentes